ONCOLOGY

Radiation dose tied to MACE, all-cause mortality.

Grade 3-5 adverse events more than doubled with triplet therapy.

Medical reversals based on clinical studies published in JAMA, the Lancet and the New England Journal of Medicine.

Incremental diagnostic yield dropped substantially after age 70-75 years.

Beyond BMI, body fat distribution shows prognostic value.

2-sample tests were thought to offer greater sensitivity with intermittent bleeding.

More than 100,000 women were followed for median of 9.5 years.

Audit of the two-week pathway for patients with suspected cancer of the head and neck and the influence of socioeconomic status.

Immune checkpoint inhibitors show efficacy in a small number of patients.

The service will be operational by spring 2020.

Final data from the PHARE trial support the current 12-month course.

Surgeons, medical oncologists and gastrointestinal oncologists reviewed current evidence.

Guidelines prepared by the UK National Co-ordinating Committee of Breast Pathology.

An analysis of data from the Hospital Episode Statistics over a 10-year period